RxDoctor Payments Data

Tammam Obeid

Vascular Surgery · Mesquite, TXNPI 1023467461

Payments from drug & device makers

What this record shows

This record is dominated by other: $25,493 of the $38,476 with a category attached, or 66.3%. Angiodynamics, Inc. accounts for 67.6% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2024 at $16,579 and has fallen 55.1% since, to $7,447 in 2025.

$38,476in general payments, 2019–2025

Across 189 payments — averaging $203.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$26K
  • Philips North America LLC$6K
  • Medtronic$1K
  • W. L. Gore & Associates, Inc.$687
  • Veryan Medical Incorporated$685
  • Bolton Medical Inc$642
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$4,00010%
  • Travel & lodging$6812%
  • Food & beverage$8,05221%
  • Education$2501%
  • Other$25,49366%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,476 in reported general payments places this provider in the 85th percentile of 347 vascular surgery providers in Texas.

See all vascular surgery providers in Texas →

Medicare billing

Part B allowed, 2024
$910,899
Medicare patients
283
Services billed
1,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban34$24,373
ClopidogrelClopidogrel Bisulfate185$1,057

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Mesquite

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →